Wire
Karyopharm to Report Data From Phase 3 Trial of Selinexor Plus Ruxolitinib in Myelofibrosis
Karyopharm Therapeutics (KPTI) said Tuesday that a late-breaking abstract from its phase 3 trial of selinexor combined with ruxolitinib in myelofibrosis was accepted for an oral presentation at the 2026 European Hematology Association Congress in mid-June.The company said new data will highlight a post-hoc analysis of 24 patients from phase 1 of the trial, which indicates that achieving a spleen volume reduction of 35% or more may predict overall survival, consistent with a similar analysis from the phase 3 trial.Shares of Karyopharm Therapeutics were down more than 8% in Tuesday trading.Price: $8.99, Change: $-0.84, Percent Change: -8.50%
$KPTI
